FindTrial
Sign In

Evaluation of blood transfusion intervals in patients with ß-thalassemia major before and after administration of hydroxyurea

Evaluation of blood transfusion intervals in patients with ß-thalassemia major before and after administration of hydroxyurea

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180707040371N1
Enrollment
20
Registered
2018-12-15
Start date
2017-09-11
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beta-thalassemia Major disease. Beta thalassemia

Interventions

Intervention group: hydroxy urea capsule (500 mg capsules)made by Apotex Canada with a dose of 20to30mg / kg for 6 months.

Sponsors

Gorgan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 18 Years

Inclusion criteria

Inclusion criteria: All patients are ß-thalassemia major who have been treated with blood transfusion, and after approval of the plan, they are treated monthly with hydroxyurea for 6 months.

Exclusion criteria

Exclusion criteria: Patients who do not tend to take oral medications Patients with unstable hemodynamic status

Design outcomes

Primary

MeasureTime frame
Blood transfusion intervals in patients. Timepoint: Frequency of blood transfusion in patients at baseline and then monthly for 6 months after administration of hydroxyurea. Method of measurement: cell blood count-patient files.;Hemoglobin total measurement. Timepoint: Hemoglobin total measurements at baseline and then monthly for 6 months after administration of hydroxyurea. Method of measurement: CBC.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges Beigom Mirbehbahani

Gorgan University of Medical Sciences

www.mirbeh@goums.ac.ir+98 17 3232 8539

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026